The LATTICE trial found no cognitive benefit from lithium supplementation in Alzheimer's disease, challenging earlier observational evidence suggesting neuroprotective effects. This null result reshapes the evidence landscape for lithium as a preventive intervention and highlights the gap between population-level associations and clinical efficacy in neurodegenerative disease.
Key Points
- LATTICE trial showed no cognitive decline slowing from lithium treatment
- Observational studies suggested neuroprotection; RCT contradicted those findings
- Null results reframe lithium's role in dementia prevention strategies
Longevity Analysis
The disconnect between observational data and randomized evidence for lithium illustrates a persistent challenge in longevity science: distinguishing true causal interventions from correlational artifacts. When population studies suggest benefit but controlled trials do not, it signals the need for more rigorous mechanistic understanding before clinical adoption. This matters because cognitive resilience depends on multiple converging inputs—energy production, circulatory efficiency, nervous system integrity, hormonal signaling, and inflammatory regulation all play roles that lithium may only partially address, if at all. Practitioners evaluating lithium for neuroprotection must now weigh the null trial against earlier favorable signals, recognizing that biological plausibility does not guarantee clinical translation.
Original published by Peter Attia MD, by Peter Attia.